In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan implements three-stage plan for reimbursement cuts in April 2006 revision round

This article was originally published in Clinica

Executive Summary

Japan's biannual reimbursement cuts, which are due to come into effect on April 1, include the unusual provision that they will be introduced over three phases (April 2006, January 2007 and April 2007).

You may also be interested in...



Generic Drug User Fee Program Sees First-Ever Fee Spending Decrease, FTE Decline

Thanks in part to budget authority bump, US FDA’s generic user fee revenue spending dropped in FY 2019, and hiring problems lead to an FTE decrease. The useable GDUFA carryover balance also increased in conjunction with the user fee revenue spending reduction, from $158.7m available at the end of FY 2018 to $199.2m at the end of FY 2019.

Lilly Bars Contract Pharmacies From 340B Discounts Despite HRSA Guidance

Distribution limits for Cialis prompts concerns among 340B-eligible providers that Lilly will impose similar restrictions for additional products and that other manufacturers may follow suit.

US FDA Restarting Domestic Inspections, Prioritizing Areas With Low Covid-19 Rates

The agency is resuming domestic inspections using a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.

Topics

UsernamePublicRestriction

Register

ID1131499

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel